Table 1– Characteristics of the included studies (also stratified for adults and children)
VariableAll individualsAdultsChildren
Country#
 South Africa6/35 (17.1)5/31 (16.1)1/4 (25.0)
 Italy5/35 (14.3)4/31 (12.9)1/4 (25.0)
 Germany5/35 (14.3)5/31 (16.1)
 Korea4/35 (11.4)4/31 (12.9)
 UK2/35 (5.7)2/4 (50.0)
 Other13/35 (37.1)13/31 (41.9)
Studies27/27 (100.0)23/27 (85.2)4/27 (14.8)
Length of study months16.8±8.716.2±7.923±10.4
Prospective design26/27 (96.3)23/23 (100)3/4 (75)
Individuals enrolled91 (148)89 (131)204.5 (75.5)
Studies enrolling immunocompromised patients17/21 (81)15/18 (83.3)1/4 (25.0)
Studies enrolling HIV+ patients14/21 (66.7)13/15 (86.6)1/4 (25.0)
Proportion of immunocompromised patients enrolled per study28.3 (42.1)30.8 (37.8)NA
Immunocompromised patients enrolled per study20 (38)24 (39.5)NA
Male:female ratio2262:1559 (1.45:1)1818:1167 (1.56:1)444:392 (1.13:1)
Proportion of BCG immunised per study53.8±25.342.1±19.974.2±21.4
Number of BCG immunised per study62 (141)27 (58)201 (39.75)
Proportion of AFB smear positive patients20 (41.6)25 (45)
Diagnostic assays
 T-SPOT.TB® and TST11/27 (40.8)10/23 (43.5)1/4 (25.0)
 QFT-G-IT and TST4/27 (14.8)3/23 (13.0)1/4 (25.0)
 T-SPOT.TB®, QFT-G-IT and TST4/27 (14.8)2/23 (8.7)2/4 (50.0)
 Others (IGRAs only)8/27 (29.6)8/23 (34.8)
  • Data are presented as n/n total (%), mean±sd or median (interquartile range), unless otherwise stated. BCG: bacille Calmette–Guérin; AFB: acid fast bacilli; TST: tuberculin skin test; QFT-G-IT: QuantiFERON-TB® Gold in-tube; IGRA: interferon-γ release assay. #: 35 countries contributed to 27 studies.